- Active, not recruiting
NCT03412565: Phase 2 - Subcutaneous Daratumumab in Combination With Standard MM Regimens - PLEIADES
Updated: May 24, 2022
PLEIADES study
A Study to Evaluate Subcutaneous Daratumumab in Combination With Standard Multiple Myeloma Treatment Regimen

MMY2040 (PLEIADES) Study
NDMM : Newly diagnosed Multiple Myeloma
RRMM : Relapsed & Refractory Multiple Myeloma
PLEIADES is a multicentre, open-label, Phase II study to investigate the safety and efficacy of DARA SC with standard-of-care regimens, including VRd (D-VRd) in patients with NDMM who are eligible for autologous stem cell transplant (ASCT), VMP (D-VMP) in ASCT-ineligible patients with NDMM and Rd (D-Rd) in patients with RRMM who received ≥1 prior line of therapy
Experimental: Daratumumab(D) + Bortezomib + Lenalidomide + Dexamethasone (D-VRd)
Experimental: Daratumumab + Bortezomib + Melphalan + Prednisone (D-VMP)
Experimental: Daratumumab + Lenalidomide + Dexamethasone (D-Rd)
Experimental: Daratumumab + Carfilzomib + Dexamethasone (D-Kd)
The purpose of this study is to evaluate the clinical benefit of subcutaneous (SC) daratumumab administered in combination with standard multiple myeloma (MM) regimens in participants with MM as measured by overall response rate (ORR) or very good partial response (VGPR) or better rate.
Sponsor
Janssen Research & Development, LLC
Multiple Locations
International Study
ClinicalTrials.gov Identifier: NCT03412565